Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert Leslie McKenzie
Date of appointment	26 June 2025

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

Mr Robert Leslie McKenzie- Unlisted Options exercisable at \$0.07 expiring 27 June 2028.

5,000,000 - Unlisted options

11/3/2002 Appendix 3X Page 1

⁺ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
Kilkenny Nominees Pty Ltd <robert a="" c="" family="" mckenzie=""> Director, shareholder and beneficiary</robert>	5,781,475 - Ordinary Shares 3,854,317- Performance Shares

Part 3 - Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

-
-
-
-

Appendix 3X Page 2 11/3/2002

⁺ See chapter 19 for defined terms.

Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Damien John Fry
Date of appointment	26 June 2025

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

Mr Paul Damien John Fry - Unlisted Options exercisable at \$0.07 expiring 27 June 2028. 5,000,000 – Unlisted options

11/3/2002 Appendix 3X Page 1

⁺ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
Mount Royal Pty Ltd <the family="" fry="" trust=""> Shareholder and Beneficiary</the>	7,784,545 - Ordinary Shares 5,189,697 - Performance Shares
Mr Paul Damien John Fry & Ms Gillian Laura Evans <fry a="" c="" evans="" fund="" superannuation=""> Beneficiary</fry>	5,698,416 - Ordinary Shares 3,798,944 - Performance Shares

Part 3 - Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

-
-
-
-

Appendix 3X Page 2 11/3/2002

⁺ See chapter 19 for defined terms.